The drug may slow the progression of Alzheimer’s disease, but it doesn’t improve the symptoms. It’s also incredibly expensive.
Articles on dementia drugs
Displaying all articles
Donanemab will only be available via private healthcare.
The drug has been hailed as a ‘turning point’ in Alzheimer’s treatment. But keep in mind the trial only included participants with early or mild disease. And while it slowed decline, it’s not a cure.
Two new dementia drugs are being hailed as breakthroughs. But what might be an incremental breakthrough for researchers, doesn’t mean a cure for patients.
Top contributors
-
Head of Clinical Services, Dementia Support Australia, & Associate Professor of Psychiatry, Monash University
-
Associate Professor, Turner Institute for Brain and Mental Health, Monash University
-
Postdoctoral Research Fellow (Neuropsychology), Monash University
-
PhD Candidate, Neuroscience, University of Sheffield